Gain Therapeutics Releases Clinical Data Supporting GT-02287 Efficacy in Parkinson's Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Should l Buy GANX?
Gain Therapeutics provided additional biomarker and clinical data from the Phase 1b clinical study of GT-02287 in people with Parkinson's disease, PD, with or without a GBA1 mutation that further supports the disease-modifying potential of GT-02287. In participants with elevated baseline levels of glucosylsphingosine in cerebrospinal fluid, CSF, at baseline, GluSph decreased by an average of 81% after 90 days of treatment with GT-02287. Elevated GluSph, a hallmark of GCase dysfunction, has been shown to increase the aggregation of alpha synuclein and to impair mitochondrial function and other intracellular processes in neurons. The reduction in GluSph in CSF, a first-ever observation following the administration of a GCase modulator to PD patients, suggests increased GCase activity in the brain, which is expected to impact the progression of Parkinson's disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GANX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GANX
Wall Street analysts forecast GANX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.940
Low
5.00
Averages
7.50
High
10.00
Current: 1.940
Low
5.00
Averages
7.50
High
10.00
About GANX
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gain Therapeutics Reports FY EPS Beat
- Earnings Performance: Gain Therapeutics reported a FY GAAP EPS of -$0.61, beating expectations by $0.03, indicating gradual financial improvement despite ongoing challenges.
- Cash Position: As of December 31, 2025, the company held $20.8 million in cash, cash equivalents, and marketable securities, doubling from $10.4 million a year earlier, showcasing significant progress in financial management.
- Market Reaction: Although still in a loss position, the earnings beat may boost investor confidence, likely leading to a positive impact on stock price and attracting more attention and investment.
- Future Outlook: With increased cash reserves, Gain Therapeutics is positioned to enhance R&D investments, driving the development and marketing of new drugs, thereby strengthening its competitive edge in the biopharmaceutical sector.
See More
GAIN THERAPEUTICS INC Reports $20.2 Million Net Loss for 2025, Equivalent to $0.61 Per Share
- Financial Performance: Gain Therapeutics reported a net loss of $20.2 million for the year 2025, equating to a loss of $0.61 per share.
- Market Impact: The financial results may influence investor sentiment and the company's stock performance in the upcoming quarters.
See More
Gain Therapeutics Attends J.P. Morgan Healthcare Conference to Showcase GT-02287
- Conference Participation: Gain Therapeutics will attend several key forums during the J.P. Morgan Healthcare Conference from January 11 to 14, showcasing its latest advancements in Parkinson's disease treatment to enhance its visibility in the biotech industry.
- Drug Development: The lead drug candidate GT-02287 is currently undergoing a Phase 1b clinical trial primarily assessing its safety and tolerability in Parkinson's patients, which is expected to lay the groundwork for future market introduction.
- Funding Support: Gain's GT-02287 program has received funding from The Michael J. Fox Foundation and the European Union, indicating its development potential and market recognition, which may accelerate clinical progress.
- Technology Platform: Gain leverages its advanced Magellan™ platform to expedite drug discovery, focusing on developing treatments for neurodegenerative diseases, showcasing the company's innovative capabilities in the biotech sector.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
Gain Therapeutics Hosts KOL Event on Parkinson's Disease Biomarkers and GT-02287
- Event Announcement: Gain Therapeutics will host a KOL virtual event on January 6, 2026, featuring renowned experts from Tel Aviv University and Harvard University to discuss biomarkers and disease modification potential of GT-02287 in Parkinson's disease.
- Clinical Research Insights: The event will review biomarker results from the Phase 1b clinical study of GT-02287, demonstrating its disease-modifying potential in Parkinson's disease patients, which could pave the way for new treatment strategies.
- Expert Backgrounds: Dr. Roy Alcalay and Dr. Peter Lansbury will share insights from their extensive research in Parkinson's disease, with Alcalay focusing on movement disorders and Lansbury on biochemical processes underlying neurodegeneration.
- Funding Support: Gain Therapeutics' GT-02287 program has received funding from The Michael J. Fox Foundation and the European Union, highlighting its potential significance and market prospects in the treatment of Parkinson's disease.
See More
Gain Therapeutics Hosts KOL Event on Parkinson's Disease Biomarkers and GT-02287
- Event Announcement: Gain Therapeutics will host a KOL virtual event on January 6, 2026, featuring experts from Tel Aviv University and Harvard to discuss biomarker data and disease-modifying potential of GT-02287 in Parkinson's disease.
- Clinical Trial Update: GT-02287 is currently undergoing a Phase 1b clinical trial to evaluate its safety and tolerability in Parkinson's patients, with participants being treated for three months across seven sites in Australia.
- Funding Support Context: Gain's Parkinson's program has received funding from The Michael J. Fox Foundation and other organizations, indicating strong early-stage development potential and market validation for the therapy.
- Drug Mechanism Overview: GT-02287 is an orally administered small molecule designed to restore enzyme activity lost due to GBA1 mutations, with preclinical data showing significant effects on motor function improvement and reduction of neuroinflammation.
See More
Gain Therapeutics Reports FY EPS Beat
- Earnings Performance: Gain Therapeutics reported a FY GAAP EPS of -$0.61, beating expectations by $0.03, indicating gradual financial improvement despite ongoing challenges.
- Cash Position: As of December 31, 2025, the company held $20.8 million in cash, cash equivalents, and marketable securities, doubling from $10.4 million a year earlier, showcasing significant progress in financial management.
- Market Reaction: Although still in a loss position, the earnings beat may boost investor confidence, likely leading to a positive impact on stock price and attracting more attention and investment.
- Future Outlook: With increased cash reserves, Gain Therapeutics is positioned to enhance R&D investments, driving the development and marketing of new drugs, thereby strengthening its competitive edge in the biopharmaceutical sector.
See More
GAIN THERAPEUTICS INC Reports $20.2 Million Net Loss for 2025, Equivalent to $0.61 Per Share
- Financial Performance: Gain Therapeutics reported a net loss of $20.2 million for the year 2025, equating to a loss of $0.61 per share.
- Market Impact: The financial results may influence investor sentiment and the company's stock performance in the upcoming quarters.
See More
Gain Therapeutics Attends J.P. Morgan Healthcare Conference to Showcase GT-02287
- Conference Participation: Gain Therapeutics will attend several key forums during the J.P. Morgan Healthcare Conference from January 11 to 14, showcasing its latest advancements in Parkinson's disease treatment to enhance its visibility in the biotech industry.
- Drug Development: The lead drug candidate GT-02287 is currently undergoing a Phase 1b clinical trial primarily assessing its safety and tolerability in Parkinson's patients, which is expected to lay the groundwork for future market introduction.
- Funding Support: Gain's GT-02287 program has received funding from The Michael J. Fox Foundation and the European Union, indicating its development potential and market recognition, which may accelerate clinical progress.
- Technology Platform: Gain leverages its advanced Magellan™ platform to expedite drug discovery, focusing on developing treatments for neurodegenerative diseases, showcasing the company's innovative capabilities in the biotech sector.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
Gain Therapeutics Hosts KOL Event on Parkinson's Disease Biomarkers and GT-02287
- Event Announcement: Gain Therapeutics will host a KOL virtual event on January 6, 2026, featuring renowned experts from Tel Aviv University and Harvard University to discuss biomarkers and disease modification potential of GT-02287 in Parkinson's disease.
- Clinical Research Insights: The event will review biomarker results from the Phase 1b clinical study of GT-02287, demonstrating its disease-modifying potential in Parkinson's disease patients, which could pave the way for new treatment strategies.
- Expert Backgrounds: Dr. Roy Alcalay and Dr. Peter Lansbury will share insights from their extensive research in Parkinson's disease, with Alcalay focusing on movement disorders and Lansbury on biochemical processes underlying neurodegeneration.
- Funding Support: Gain Therapeutics' GT-02287 program has received funding from The Michael J. Fox Foundation and the European Union, highlighting its potential significance and market prospects in the treatment of Parkinson's disease.
See More
Gain Therapeutics Hosts KOL Event on Parkinson's Disease Biomarkers and GT-02287
- Event Announcement: Gain Therapeutics will host a KOL virtual event on January 6, 2026, featuring experts from Tel Aviv University and Harvard to discuss biomarker data and disease-modifying potential of GT-02287 in Parkinson's disease.
- Clinical Trial Update: GT-02287 is currently undergoing a Phase 1b clinical trial to evaluate its safety and tolerability in Parkinson's patients, with participants being treated for three months across seven sites in Australia.
- Funding Support Context: Gain's Parkinson's program has received funding from The Michael J. Fox Foundation and other organizations, indicating strong early-stage development potential and market validation for the therapy.
- Drug Mechanism Overview: GT-02287 is an orally administered small molecule designed to restore enzyme activity lost due to GBA1 mutations, with preclinical data showing significant effects on motor function improvement and reduction of neuroinflammation.
See More
